Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Neurons: Neurotransmission01:27

Adrenergic Neurons: Neurotransmission

5.1K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
5.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.0K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.0K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.5K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.7K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.7K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Base-Catalyzed Aldol Addition Reaction01:08

Base-Catalyzed Aldol Addition Reaction

4.3K
As depicted in Figure 1, base-catalyzed aldol addition involves adding two carbonyl compounds in aqueous sodium hydroxide to form a β-hydroxy carbonyl compound.
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac Sympathetic Neuroimaging in Autonomic Synucleinopathies: <sup>123</sup>I-Metaiodobenzylguanidine and <sup>18</sup>F-Dopamine.

Movement disorders clinical practice·2026
Same author

Putamen Dopamine Synthesis, Vesicular Storage, and Metabolism in Patients With Parkinson Disease.

Neurology·2026
Same author

Catecholamine metabolism revisited: From neurochemistry to integrative physiology and pathophysiology.

Physiological reviews·2026
Same author

Central noradrenergic deficiency in post-infectious chronic fatigue: neurobehavioral correlates.

Brain communications·2026
Same author

Distinct Sympathoneural and Cardiovagal Domains of Arterial Baroreflex Function in Autonomic Synucleinopathies.

Research square·2026
Same author

Putamen dopamine synthesis, vesicular storage, and metabolism in Parkinson disease.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jan 2, 2026

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites
13:35

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites

Published on: March 1, 2018

15.2K

The catecholaldehyde hypothesis: where MAO fits in.

David S Goldstein1

  • 1Autonomic Medicine Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological, Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike MSC-1620, Building 10 Room 8N260, Bethesda, MD, 20892-1620, USA. goldsteind@ninds.nih.gov.

Journal of Neural Transmission (Vienna, Austria : 1996)
|December 7, 2019
PubMed
Summary
This summary is machine-generated.

Monoamine oxidase (MAO) produces toxic DOPAL from dopamine. This toxic intermediate interacts with alpha-synuclein, contributing to neurodegenerative diseases like Parkinson's. A combined MAO inhibitor and antioxidant strategy may offer neuroprotection.

Keywords:
Alpha-synucleinDOPALDopamineMonoamine oxidase

More Related Videos

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.3K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.7K

Related Experiment Videos

Last Updated: Jan 2, 2026

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites
13:35

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites

Published on: March 1, 2018

15.2K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.3K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.7K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Toxicology

Background:

  • Monoamine oxidase (MAO) metabolizes key neurotransmitters like dopamine.
  • 3,4-dihydroxyphenylacetaldehyde (DOPAL) is a toxic byproduct of MAO acting on dopamine.
  • DOPAL accumulation is linked to neurodegenerative diseases via alpha-synuclein interactions.

Purpose of the Study:

  • To review the role of DOPAL in catecholaminergic neurodegeneration.
  • To explore the catecholaldehyde hypothesis linking DOPAL, alpha-synuclein, and Lewy body diseases.
  • To evaluate potential neuroprotection strategies.

Main Methods:

  • Review of existing literature on MAO, DOPAL, and alpha-synuclein.
  • Discussion of enzymatic pathways involving MAO and aldehyde dehydrogenase (ALDH).
  • Analysis of the proposed vicious cycles of toxicity.

Main Results:

  • DOPAL toxicity arises from its interaction with alpha-synuclein, promoting oligomerization and Lewy body formation.
  • A cycle of oxidative stress, hydrogen peroxide generation, and lipid peroxidation exacerbates DOPAL accumulation by inhibiting ALDH.
  • MAO inhibition reduces DOPAL but may increase dopamine oxidation, suggesting a trade-off.

Conclusions:

  • The catecholaldehyde hypothesis provides a framework for understanding neurodegeneration in Parkinson disease and related disorders.
  • Concurrent inhibition of MAO and antioxidant treatment is proposed as a potential neuroprotective strategy.
  • Further research is needed to validate therapeutic interventions targeting the MAO-DOPAL-alpha-synuclein axis.